Mathias Kunz1,2, Nathalie Lisa Albert3,2, Marcus Unterrainer3,2, Christian la Fougere3,4, Rupert Egensperger5,2, Ulrich Schüller5,6,7,8, Juergen Lutz9, Simone Kreth10, Jörg-Christian Tonn1,2, Friedrich-Wilhelm Kreth1,2, Niklas Thon1,2. 1. Department of Neurosurgery, University of Munich, Munich, Germany. 2. German Cancer Consortium, partner site Munich, Germany. 3. Department of Nuclear Medicine, University of Munich, Munich, Germany. 4. Division of Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University of Tübingen, Tübingen, Germany. 5. Center for Neuropathology, University of Munich, Munich, Germany. 6. Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 7. Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 8. Research Institute Children's Cancer Center Hamburg, Hamburg, Germany. 9. Department of Clinical Radiology, University of Munich, Munich, Germany. 10. Department of Anaesthesiology, University of Munich, Munich, Germany.
Abstract
BACKGROUND: We aimed to elucidate the place of dynamic O-(2-[18F]-fluoroethyl)-L-tyrosine (18F-FET) PET in prognostic models of gadolinium (Gd)-negative gliomas. METHODS: In 98 patients with Gd-negative gliomas undergoing 18F-FET PET guided biopsy, time activity curves (TACs) of each tumor were qualitatively categorized as either increasing or decreasing. Additionally, post-hoc quantitative analyses were done using minimal time-to-peak (TTPmin) measurements. Prognostic factors were obtained from multivariate hazards models. The fit of the biospecimen- and imaging-derived models was compared. RESULTS: A homogeneous increasing, mixed, and homogeneous decreasing TAC pattern was seen in 51, 19, and 28 tumors, respectively. Mixed TAC tumors exhibited both increasing and decreasing TACs. Corresponding adjusted 5-year survival was 85%, 47%, and 19%, respectively (P < 0.001). Qualitative and quantitative TAC measurements were highly intercorrelated (P < 0.0001). TTPmin was longest (shortest) in the homogeneous increasing (decreasing) TAC group and in between in the mixed TAC group. TTPmin was longer in isocitrate dehydrogenase (IDH)-mutant tumors (P < 0.001). Outcome was similarly precisely predicted by biospecimen- and imaging-derived models. In the biospecimen model, World Health Organization (WHO) grade (P < 0.0001) and IDH status (P < 0.001) were predictors for survival. Outcome of homogeneous increasing (homogeneous decreasing) TAC tumors was nearly identical, with both TTPmin > 25 min (TTPmin ≤ 12.5 min) tumors and IDH-mutant grade II (IDH-wildtype) gliomas. Outcome of mixed TAC tumors matched that of both intermediate TTPmin (>12.5 min and ≤25 min) and IDH-mutant, grade III gliomas. Each of the 3 prognostic clusters differed significantly from the other ones of the respective models (P < 0.001). CONCLUSION: TAC measurements constitute a powerful biomarker independent from tumor grade and IDH status.
BACKGROUND: We aimed to elucidate the place of dynamic O-(2-[18F]-fluoroethyl)-L-tyrosine (18F-FET) PET in prognostic models of gadolinium (Gd)-negative gliomas. METHODS: In 98 patients with Gd-negative gliomas undergoing 18F-FET PET guided biopsy, time activity curves (TACs) of each tumor were qualitatively categorized as either increasing or decreasing. Additionally, post-hoc quantitative analyses were done using minimal time-to-peak (TTPmin) measurements. Prognostic factors were obtained from multivariate hazards models. The fit of the biospecimen- and imaging-derived models was compared. RESULTS: A homogeneous increasing, mixed, and homogeneous decreasing TAC pattern was seen in 51, 19, and 28 tumors, respectively. Mixed TAC tumors exhibited both increasing and decreasing TACs. Corresponding adjusted 5-year survival was 85%, 47%, and 19%, respectively (P < 0.001). Qualitative and quantitative TAC measurements were highly intercorrelated (P < 0.0001). TTPmin was longest (shortest) in the homogeneous increasing (decreasing) TAC group and in between in the mixed TAC group. TTPmin was longer in isocitrate dehydrogenase (IDH)-mutant tumors (P < 0.001). Outcome was similarly precisely predicted by biospecimen- and imaging-derived models. In the biospecimen model, World Health Organization (WHO) grade (P < 0.0001) and IDH status (P < 0.001) were predictors for survival. Outcome of homogeneous increasing (homogeneous decreasing) TAC tumors was nearly identical, with both TTPmin > 25 min (TTPmin ≤ 12.5 min) tumors and IDH-mutant grade II (IDH-wildtype) gliomas. Outcome of mixed TAC tumors matched that of both intermediate TTPmin (>12.5 min and ≤25 min) and IDH-mutant, grade III gliomas. Each of the 3 prognostic clusters differed significantly from the other ones of the respective models (P < 0.001). CONCLUSION: TAC measurements constitute a powerful biomarker independent from tumor grade and IDH status.
Authors: Nathalie L Albert; Isabel Winkelmann; Bogdana Suchorska; Vera Wenter; Christine Schmid-Tannwald; Erik Mille; Andrei Todica; Matthias Brendel; Jörg-Christian Tonn; Peter Bartenstein; Christian la Fougère Journal: Eur J Nucl Med Mol Imaging Date: 2015-12-15 Impact factor: 9.236
Authors: Michael Weller; Martin van den Bent; Jörg C Tonn; Roger Stupp; Matthias Preusser; Elizabeth Cohen-Jonathan-Moyal; Roger Henriksson; Emilie Le Rhun; Carmen Balana; Olivier Chinot; Martin Bendszus; Jaap C Reijneveld; Frederick Dhermain; Pim French; Christine Marosi; Colin Watts; Ingela Oberg; Geoffrey Pilkington; Brigitta G Baumert; Martin J B Taphoorn; Monika Hegi; Manfred Westphal; Guido Reifenberger; Riccardo Soffietti; Wolfgang Wick Journal: Lancet Oncol Date: 2017-05-05 Impact factor: 41.316
Authors: Niklas Thon; Mathias Kunz; Lena Lemke; Nathalie L Jansen; Sabina Eigenbrod; Simone Kreth; Jürgen Lutz; Rupert Egensperger; Armin Giese; Jochen Herms; Michael Weller; Hans Kretzschmar; Jörg-Christian Tonn; Christian la Fougère; Friedrich-Wilhelm Kreth Journal: Int J Cancer Date: 2014-11-03 Impact factor: 7.396
Authors: Florian Stockhammer; Michail Plotkin; Holger Amthauer; Frank K H van Landeghem; Christian Woiciechowsky Journal: J Neurooncol Date: 2008-06 Impact factor: 4.130
Authors: Olivia Kertels; Almuth F Kessler; Milena I Mihovilovic; Antje Stolzenburg; Thomas Linsenmann; Samuel Samnick; Stephanie Brändlein; Camelia Maria Monoranu; Ralf-Ingo Ernestus; Andreas K Buck; Mario Löhr; Constantin Lapa Journal: Mol Imaging Biol Date: 2019-12 Impact factor: 3.488
Authors: Aliaksandra Shymanskaya; Wieland A Worthoff; Gabriele Stoffels; Johannes Lindemeyer; Bernd Neumaier; Philipp Lohmann; Norbert Galldiks; Karl-Josef Langen; N Jon Shah Journal: Mol Imaging Biol Date: 2020-02 Impact factor: 3.488
Authors: Nathalie L Albert; Lena Kaiser; Zhicong Li; Adrien Holzgreve; Lena M Unterrainer; Viktoria C Ruf; Stefanie Quach; Laura M Bartos; Bogdana Suchorska; Maximilian Niyazi; Vera Wenter; Jochen Herms; Peter Bartenstein; Joerg-Christian Tonn; Marcus Unterrainer Journal: Eur J Nucl Med Mol Imaging Date: 2022-10-13 Impact factor: 10.057
Authors: Elena K Bauer; Gabriele Stoffels; Tobias Blau; Guido Reifenberger; Jörg Felsberg; Jan M Werner; Philipp Lohmann; Jurij Rosen; Garry Ceccon; Caroline Tscherpel; Marion Rapp; Michael Sabel; Christian P Filss; Nadim J Shah; Bernd Neumaier; Gereon R Fink; Karl-Josef Langen; Norbert Galldiks Journal: Eur J Nucl Med Mol Imaging Date: 2020-02-07 Impact factor: 9.236
Authors: Zhicong Li; Lena Kaiser; Adrien Holzgreve; Viktoria C Ruf; Bogdana Suchorska; Vera Wenter; Stefanie Quach; Jochen Herms; Peter Bartenstein; Jörg-Christian Tonn; Marcus Unterrainer; Nathalie L Albert Journal: Eur J Nucl Med Mol Imaging Date: 2021-09-07 Impact factor: 9.236